

# Pantera™ Lux™

Drug-Coated Balloon  
Catheter (DCB)

Clinically proven. Best in class<sup>1</sup> crossability.




# Pantera™ Lux™ DCB

Clinically proven. Best in class<sup>1</sup> crossability.

## Clinically proven solution for in-stent-restenosis and further indications<sup>2-13</sup>

Pantera™ Lux™ DCB has proven efficacy and safety in multiple clinical trials investigating coronary drug-coated balloons for various implant-free treatment options:<sup>2-11</sup>



DCB is confirmed as a viable treatment option for ISR with the advantage of avoiding an additional stent layer.


The treatment with Pantera™ Lux™ DCB may represent a valuable alternative strategy in selected STEMI patients undergoing primary PCI.

## Lux™ coating technology for rapid drug absorption


The Lux™ coating technology blends paclitaxel with BTHC, a rapidly metabolized, safe and biocompatible excipient, thus improving bioavailability at the target site.<sup>15</sup>

## Prolonged tissue retention at the target site<sup>15,16</sup>


Pig coronary artery paclitaxel tissue concentrations



\* Orsiro™ DES (Teleflex™)  
\*\* Orsiro™ DES (Teleflex™) or Xience DES (Abbott)



**3,700+**  
**patients**  
treated in clinical  
studies<sup>2-14</sup> with  
Pantera™ Lux™ DCB




**82 %**  
easier crossability  
vs. RESTORE<sup>16</sup>

Excellent deliverability

Pantera™ Lux™ DCB, with its lowest crossing profile, provides better pushability and easier crossability.<sup>16</sup>


Lowest crossing profile<sup>16</sup>

Pantera™ Lux™ DCB has a **44% smaller crossing profile**.




Better pushability<sup>16</sup>

**136% more force transmitted** from hub to distal tip.



Best in class crossability<sup>16</sup>

**82% less force needed** to cross lesions.



References

- 1 Data on file, when comparing solely to main competitor coronary drug-coated balloon (DCB) catheters 3.0/20: Agent, SeQuent Please NEO, IN.PACT Falcon, MagicTouch and RESTORE.
- 2 Tölg R et al. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELux registry EuroIntervention. 2014; 10(5). 591-599.
- 3 Hehrlein C et al. Twelve-month results of a Paclitaxel Releasing Balloon in Patients Presenting with In-stent Restenosis First-in-Man (PEPPER) trial. Cardiovascular Revascularization Medicine. 2012; 13 (5): 260-264.
- 4 Kufner S, Joner M, Schneider S et al. NeoIntimal Modification With Scoring Balloon and Efficacy of Drug-Coated Balloon Therapy in Patients With Restenosis in Drug-Eluting Coronary Stents. JACC Cardiovasc Interv. 2017; 10(13). 1332-1340.
- 5 Jensen C et al. Angiographic and clinical performance of a paclitaxel-coated balloon compared to a second-generation sirolimus-eluting stent in patients with in-stent restenosis: the BIOLUX randomised controlled trial. EuroIntervention. 2018; 14: 1096-1103.
- 6 Nguyen V.P.T et al. Comparison of clinical outcomes of two different types of paclitaxel-coated balloons for treatment of patients with coronary in-stent restenosis. Heart and Vessels. 2019. 1-9. doi: 10.1007/s00380-019-01388.
- 7 Assadi-Schmidt A et al. SeQuent Please vs. Pantera Lux drug coated balloon angioplasty in real life: Results from the Düsseldorf DCB registry, Int J Cardiol. 2016. doi: 10.1016/j.ijcard.2016.12.022.
- 8 Vos NS et al. Safety and feasibility of a Paclitaxel-eluting balloon angioplasty in Primary Percutaneous coronary intervention in Amsterdam (PAPPA): one year clinical outcome of a pilot study. EuroIntervention. 2014; 10(5). 584-590.
- 9 Vos N S et al. Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction (The REVELATION Randomized Trial). JACC: Cardiovascular Interventions. 2019; 1-9, doi:10.1016/j.jcin.2019.04.016.
- 10 Worthley S, Hendriks R, Worthley M et al. Paclitaxel-eluting balloon and everolimus-eluting stent for provisional stenting of coronary bifurcations: 12-months results of the multicenter BIOLUX-I study. Cardiovasc Revasc. Med. 2015; 16(7). 413-417.
- 11 Jim MH et al. Six month angiographic result of supplementary paclitaxel-eluting balloon deployment to treat side branch ostium narrowing (SARPEDON). Int J Cardiol. 2015; 187:594-597.
- 12 Roncalli J et al. Paclitaxel Drug-Coated Balloon After Bare-Metal Stent Implantation, an Alternative Treatment to Drug-Eluting Stent in High Bleeding Risk Patients (The Panelux Trial). J INVASIVE CARDIOL. 2019;31(4):94-100.
- 13 García-Touchard A, Goicolea J, Sabaté M et al. A randomised trial of paclitaxel-eluting balloon after bare metal stent implantation vs. bare metal stent in ST-elevation myocardial infarction (the PEBSI study). EuroIntervention. 2017; 12(13). 1587-1594.
- 14 Venetsanos D, Omerovic E, Sarno G et al. Long term outcome after treatment of de novo coronary artery lesions using three different drug coated balloons. International Journal of Cardiology. 2020; 1-7. doi: 10.1016/j.ijcard.2020.09.054.
- 15 Radke PW et al. Vascular effects of paclitaxel following drug-eluting balloon angioplasty in a porcine coronary model: the importance of excipients. EuroIntervention. 2011 Oct; 7(6): 730-7.
- 16 Data on file.

# Pantera™ Lux™ DCB

Vascular  
Intervention  
Coronary



Indicated for balloon dilatation for in-stent restenosis, de-novo lesions, acute or impending vascular occlusion and treatment of small vessel disease.\*

| Technical data               |                                                                               |
|------------------------------|-------------------------------------------------------------------------------|
| DRUG-COATED BALLOON CATHETER |                                                                               |
| Catheter type                | Fast-exchange PTCA balloon catheter                                           |
| Recommended guide catheter   | 5F (min. I.D. 0.056")                                                         |
| Lesion entry profile         | 0.017"                                                                        |
| Guide wire diameter          | 0.014"                                                                        |
| Usable catheter length       | 140 cm                                                                        |
| Balloon folding              | 3-fold                                                                        |
| Balloon markers              | Two embedded platinum-iridium markers                                         |
| Brachial shaft marker        | 92 cm from tip                                                                |
| Femoral shaft marker         | 102 cm from tip                                                               |
| Proximal shaft diameter      | 2.0F                                                                          |
| Distal shaft diameter        | 2.5F (ø 2.0–3.5 mm), 2.6F (ø 4.0 mm)                                          |
| Nominal Pressure (NP)        | 7 atm                                                                         |
| Rated Burst Pressure (RBP)   | 13 atm (ø 2.0–3.5 mm); 12 atm (ø 4.0 mm)                                      |
| COATING                      |                                                                               |
| Drug                         | Paclitaxel                                                                    |
| Drug dose                    | 3.0 µg/mm²                                                                    |
| Delivery matrix              | Paclitaxel and butyryl-tri-hexyl citrate (BTHC)                               |
| Coated area                  | Cylindrical section of the balloon, exceeding the proximal and distal markers |

| Compliance Chart           |       | BALLOON DIAMETER × LENGTH |                  |                  |                  |                  |  |
|----------------------------|-------|---------------------------|------------------|------------------|------------------|------------------|--|
|                            |       | ø 2.0 × 10–30 mm          | ø 2.5 × 10–30 mm | ø 3.0 × 10–30 mm | ø 3.5 × 10–30 mm | ø 4.0 × 10–30 mm |  |
| Nominal Pressure (NP)      | atm** | 7                         | 7                | 7                | 7                | 7                |  |
|                            | ø     | 2.00 mm                   | 2.50 mm          | 3.00 mm          | 3.50 mm          | 4.00 mm          |  |
| Rated Burst Pressure (RBP) | atm** | 13                        | 13               | 13               | 13               | 12               |  |
|                            | ø     | 2.26 mm                   | 2.82 mm          | 3.48 mm          | 4.11 mm          | 4.59 mm          |  |

\*\*1 atm = 1.013 bar

| Ordering Information |        | BALLOON Ø CATHETER LENGTH 140 CM, BALLOON LENGTH |        |        |        |       |
|----------------------|--------|--------------------------------------------------|--------|--------|--------|-------|
|                      |        | 10 mm                                            | 15 mm  | 20 mm  | 25 mm  | 30 mm |
| 2.0 mm               | 365110 | 365111                                           | 365112 | 365113 | 365114 |       |
| 2.5 mm               | 365120 | 365121                                           | 365122 | 365123 | 365124 |       |
| 3.0 mm               | 365125 | 365126                                           | 365127 | 365128 | 365129 |       |
| 3.5 mm               | 365130 | 365131                                           | 365132 | 365133 | 365134 |       |
| 4.0 mm               | 365135 | 365136                                           | 365137 | 365138 | 365139 |       |

\*Indication as per IFU (may differ in countries not accepting CE mark)

## Refer to IFU

Refer to QR code for a copy of the Instructions for Use for a complete listing of the indications, contraindications, warnings and precautions.



## About Teleflex

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people's lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™, Rüschi™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit [teleflex.com](https://teleflex.com).

## Corporate Office

Phone +1 610 225 6800, 550 E. Swedesford Road, Suite 400, Wayne, PA 19087, USA

## Regional Offices

**United States:** Phone +1 919 544 8000, Toll Free 866 246 6990, [cs@teleflex.com](mailto:cs@teleflex.com), 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

**Latin America:** Phone +1 919 433 4999, [la.cs@teleflex.com](mailto:la.cs@teleflex.com), 3015 Carrington Mill Boulevard, Morrisville, NC 27560, USA

**International:** Phone +353 (0)9 06 46 08 00, [orders.intl@teleflex.com](mailto:orders.intl@teleflex.com), Teleflex Medical Europe Ltd., IDA Business and Technology Park, Dublin Road, Athlone, Co Westmeath, Ireland

The Pantera Lux DCB with its Lux coating is part of the Lux family of paclitaxel-coated balloons.

Teleflex, the Teleflex logo, Lux, Orsiro, and Pantera are trademarks or registered trademarks of Teleflex Incorporated or its affiliates in the U.S. and/or other countries. All other names are the trademarks or registered trademarks of their respective owners.

Information in this material is not a substitute for the product Instructions for Use. Not all products may be available in all countries. Please contact your local representative.

© 2025 Teleflex Incorporated. All rights reserved.

371257-EN · REV H · 09 25 PDF